These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24498115)

  • 21. Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB.
    Abrahams KA; Cox JA; Spivey VL; Loman NJ; Pallen MJ; Constantinidou C; Fernández R; Alemparte C; Remuiñán MJ; Barros D; Ballell L; Besra GS
    PLoS One; 2012; 7(12):e52951. PubMed ID: 23300833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
    Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and in vitro antitubercular activity of pyridine analouges against the resistant Mycobacterium tuberculosis.
    Patel H; Chaudhari K; Jain P; Surana S
    Bioorg Chem; 2020 Sep; 102():104099. PubMed ID: 32711084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis.
    Hirata T; Saito H; Tomioka H; Sato K; Jidoi J; Hosoe K; Hidaka T
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2295-303. PubMed ID: 8619585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pyrazolo[1,5- a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis.
    Lu X; Williams Z; Hards K; Tang J; Cheung CY; Aung HL; Wang B; Liu Z; Hu X; Lenaerts A; Woolhiser L; Hastings C; Zhang X; Wang Z; Rhee K; Ding K; Zhang T; Cook GM
    ACS Infect Dis; 2019 Feb; 5(2):239-249. PubMed ID: 30485737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, syntheses, and anti-tuberculosis activities of conjugates of piperazino-1,3-benzothiazin-4-ones (pBTZs) with 2,7-dimethylimidazo [1,2-a]pyridine-3-carboxylic acids and 7-phenylacetyl cephalosporins.
    Majewski MW; Tiwari R; Miller PA; Cho S; Franzblau SG; Miller MJ
    Bioorg Med Chem Lett; 2016 Apr; 26(8):2068-71. PubMed ID: 26951749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model.
    Byrne ST; Denkin SM; Gu P; Nuermberger E; Zhang Y
    J Med Microbiol; 2007 Aug; 56(Pt 8):1047-1051. PubMed ID: 17644711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).
    Lupien A; Vocat A; Foo CS; Blattes E; Gillon JY; Makarov V; Cole ST
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.
    Nikonenko BV; Samala R; Einck L; Nacy CA
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4550-5. PubMed ID: 15561824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
    Matsumoto M; Hashizume H; Tomishige T; Kawasaki M; Tsubouchi H; Sasaki H; Shimokawa Y; Komatsu M
    PLoS Med; 2006 Nov; 3(11):e466. PubMed ID: 17132069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection.
    Cynamon MH; Zhang Y; Harpster T; Cheng S; DeStefano MS
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2922-4. PubMed ID: 10582883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.
    Moraski GC; Markley LD; Chang M; Cho S; Franzblau SG; Hwang CH; Boshoff H; Miller MJ
    Bioorg Med Chem; 2012 Apr; 20(7):2214-20. PubMed ID: 22391032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conjugation of a 5-nitrofuran-2-oyl moiety to aminoalkylimidazoles produces non-toxic nitrofurans that are efficacious in vitro and in vivo against multidrug-resistant Mycobacterium tuberculosis.
    Krasavin M; Lukin A; Vedekhina T; Manicheva O; Dogonadze M; Vinogradova T; Zabolotnykh N; Rogacheva E; Kraeva L; Yablonsky P
    Eur J Med Chem; 2018 Sep; 157():1115-1126. PubMed ID: 30179748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
    Hu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Liu Y; Schipani A; Davies G; Coates A
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4778-85. PubMed ID: 27216065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice.
    Vilchèze C; Kim J; Jacobs WR
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29298757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and antimycobacterial activity of some novel imidazo[1,2-c]pyrimidines.
    Chhabria MT; Jani MH
    Eur J Med Chem; 2009 Oct; 44(10):3837-44. PubMed ID: 19423196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identifying Regimens Containing TBI-166, a New Drug Candidate against
    Zhang Y; Zhu H; Fu L; Wang B; Guo S; Chen X; Liu Z; Huang H; Yang T; Lu Y
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061157
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Antoci V; Cucu D; Zbancioc G; Moldoveanu C; Mangalagiu V; Amariucai-Mantu D; Aricu A; Mangalagiu II
    Future Med Chem; 2020 Feb; 12(3):207-222. PubMed ID: 31916456
    [No Abstract]   [Full Text] [Related]  

  • 40. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.